Skip to main content

Table 1 Clinical characteristics of patients administered bosutinib

From: Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Characteristics Frequency P value
Standard dose Dose escalation
Total number 10 15  
Female: male 5:5 8:7  
Age (year) 63.0 (34.0–78.0) 55.0 (19.0–81.0) 0.183
Phase, CP: AP: BP 7:2:1 15:0:0  
Reason of taking bosutinib, TKI-R: TKI-Int: de novo CML 4:5:1 9:6:0  
Body weight (kg) 59.9 (40.8–69.1) 53.0 (44.1–86.3) 0.889
Laboratory test values
 White blood cell (*103/mm3) 8.5 (3.6–190.7) 6.1 (1.3–13.8) 0.332
 Hemoglobin (g/dL) 10.3 (8.2–14.2) 12.1 (8.3–14.8) 0.052
 Platelet (*104/mm3) 29.5 (12.1–326.0) 19.4 (12.8–162.0) 0.120
 Aspartate transaminase (IU/L) 23.0 (14.0–56.0) 24.0 (10.0–47.0) 0.487
 Alanine transaminase (IU/L) 17.5 (9.0–65.0) 23.0 (7.0–34.0) 0.232
 Serum albumin (g/dL) 4.1 (3.7–4.3) 4.2 (3.0–5.2) 0.179
 Total bilirubin (mg/dL) 0.6 (0.2–0.9) 0.6 (0.3–2.7) 0.557
 Serum creatinine (mg/dL) 0.8 (0.5–0.9) 0.7 (0.4–1.7) 0.803
 Lipase (IU/L) 21.5 (5.0–75.0) 18.0 (6.0–38.0) 0.781
  1. Data presented as number or median (minimum–maximum)
  2. TKI tyrosine kinase inhibitor, R resistance, Int intolerance